ADC Therapeutics SA
ZYNLONTA
relapsed or refractory diffuse large B-cell lymphoma
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 12h ago
“we plan to discuss the benefit-risk profile of this combination with the U.S. FDA as we prepare for the planned supplemental Biologics License Application (sBLA) filing”